The 2020 BMT CTN Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma

Sarah A. Holstein, Nizar Bahlis, P. Leif Bergsagel, Manisha Bhutani, Niccolo Bolli, Carrie Brownstein, Pierre Demolis, David Foureau, Francesca Gay, Irene M. Ghobrial, Nicole Gormley, Jens Hillengass, Martin Kaiser, Marcela V. Maus, J. Joseph Melenhorst, Maximilian Merz, Michael O. Dwyer, Bruno Paiva, Marcelo C. Pasquini, Nina ShahSandy W. Wong, Saad Z. Usmani, Philip L. McCarthy

Research output: Contribution to journalReview articlepeer-review

Abstract

The fifth annual Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma was conducted as one of the American Society of Hematology Annual Meeting Scientific Workshops on Thursday December 3, 2020. This workshop focused on four main topics: (1) integrating minimal residual disease into clinical trial design and practice; (2) the molecular and immunobiology of disease evolution and progression in myeloma; (3) adaptation of next-generation sequencing, next-generation flow cytometry, and cytometry by time of flight techniques; and (4) chimeric antigen receptor T-cell and other cellular therapies for myeloma. In this report, we provide a summary of the workshop presentations and discuss future directions in the field.

Original languageEnglish (US)
Pages (from-to)807-816
Number of pages10
JournalTransplantation and Cellular Therapy
Volume27
Issue number10
DOIs
StatePublished - Oct 1 2021

Keywords

  • CAR T-cell
  • Cellular therapy
  • Endpoint
  • Immune profiling
  • Minimal residual disease
  • Multiple myeloma

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint

Dive into the research topics of 'The 2020 BMT CTN Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma'. Together they form a unique fingerprint.

Cite this